VarmX is developing a treatment for severe bleeding in patients taking anticoagulants. The new treatment is based on administering a modified clotting protein that can stop or prevent bleeding in patients who need emergency surgery.

Mibiton is financing R&D equipment that can improve and further develop the production of the clotting protein.